| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 0 | ||||
| Sells | 6 | -86,793 | 100% | $23.96 | -$2,079,526 |
| Net | -6 | -86,793 | -100% | -$2,079,526 |
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Shawn Cross | PCRX | Common Stock | Award | 87.3% | 49,091 | 105,341 | 11 Feb 2026 | Direct | ||
| Kristen Williams | PCRX | Common Stock | Award | 41.5% | 54,546 | 185,849 | 11 Feb 2026 | Direct | ||
| Brendan Teehan | PCRX | Common Stock | Award | 105.1% | 51,714 | 100,934 | 11 Feb 2026 | Direct | ||
| Lauren Riker | PCRX | Common Stock | Award | 36.8% | 19,273 | 71,586 | 11 Feb 2026 | Direct | ||
| Jonathan Slonin | PCRX | Common Stock | Award | 31.6% | 54,546 | 226,901 | 11 Feb 2026 | Direct | ||
| Frank D. Lee | PCRX | Common Stock | Award | 65.6% | 261,818 | 660,831 | 11 Feb 2026 | Direct | ||
| Lauren Riker | PCRX | Common Stock | Sale | -7.1% | $83,240 | $20.81 | -4,000 | 52,313 | 02 Feb 2026 | Direct |
| Kristen Williams | PCRX | Common Stock | Sale | -9.1% | $269,703 | $20.53 | -13,137 | 131,303 | 02 Feb 2026 | Direct |
| Lauren Riker | PCRX | Common Stock | Tax liability | -4.66% | -2,751 | 56,313 | 30 Jan 2026 | Direct | ||
| Jonathan Slonin | PCRX | Common Stock | Tax liability | -3.46% | -6,168 | 172,355 | 30 Jan 2026 | Direct | ||
| Brendan Teehan | PCRX | Common Stock | Tax liability | -9.53% | -5,182 | 49,220 | 30 Jan 2026 | Direct | ||
| Frank D. Lee | PCRX | Common Stock | Tax liability | -9.42% | -41,488 | 399,013 | 30 Jan 2026 | Direct | ||
| Kristen Williams | PCRX | Common Stock | Tax liability | -10.6% | -17,134 | 144,440 | 30 Jan 2026 | Direct | ||
| Samit Hirawat | PCRX | Stock Option (Right to Buy) | Award | 39,291 | 39,291 | 27 Jan 2026 | Direct | |||
| Lauren Riker | PCRX | Common Stock | Sale | -2.34% | $34,324 | $24.24 | -1,416 | 59,064 | 05 Jan 2026 | Direct |
| Jonathan Slonin | PCRX | Common Stock | Tax liability | -0.21% | -381 | 178,523 | 02 Jan 2026 | Direct | ||
| Lauren Riker | PCRX | Common Stock | Tax liability | -0.26% | -159 | 60,480 | 02 Jan 2026 | Direct | ||
| Frank D. Lee | PCRX | Common Stock | Tax liability | -2.06% | -9,272 | 440,501 | 02 Jan 2026 | Direct | ||
| Brendan Teehan | PCRX | Common Stock | Award | 0.74% | 402 | 54,402 | 31 Dec 2025 | Direct | ||
| Shawn Cross | PCRX | Common Stock | Sale | -13.9% | $228,875 | $25.14 | -9,104 | 56,250 | 10 Dec 2025 | Direct |
| Shawn Cross | PCRX | Common Stock | Options Exercise | 16.2% | 9,104 | 65,354 | 10 Dec 2025 | Direct | ||
| Shawn Cross | PCRX | Stock Option (Right to Buy) | Options Exercise | -4.95% | -9,104 | 175,000 | 10 Dec 2025 | Direct | ||
| Shawn Cross | PCRX | Common Stock | Sale | -22% | $397,877 | $25.03 | -15,896 | 56,250 | 09 Dec 2025 | Direct |
| Shawn Cross | PCRX | Common Stock | Options Exercise | 28.3% | 15,896 | 72,146 | 09 Dec 2025 | Direct | ||
| Shawn Cross | PCRX | Stock Option (Right to Buy) | Options Exercise | -7.95% | -15,896 | 184,104 | 09 Dec 2025 | Direct | ||
| Jonathan Slonin | PCRX | Common Stock | Sale | -2.17% | $95,396 | $24.09 | -3,960 | 178,367 | 17 Nov 2025 | Direct |
| Shawn Cross | PCRX | Common Stock | Sale | -17.6% | $266,405 | $22.09 | -12,060 | 56,250 | 10 Nov 2025 | Direct |
| Shawn Cross | PCRX | Common Stock | Tax liability | -8.92% | -6,690 | 68,310 | 31 Oct 2025 | Direct | ||
| Abraham Ceesay | PCRX | Common Stock | Sale | -20.7% | $64,005 | $27.19 | -2,354 | 9,039 | 04 Sep 2025 | Direct |
| Marcelo Bigal | PCRX | Common Stock | Sale | -30.1% | $116,267 | $23.67 | -4,912 | 11,393 | 07 Aug 2025 | Direct |
| Jonathan Slonin | PCRX | Common Stock | Tax liability | -0.17% | -315 | 182,327 | 01 Aug 2025 | Direct | ||
| Mark A. Kronenfeld | PCRX | Common Stock | Award | 40.2% | 9,999 | 34,901 | 11 Jun 2025 | Direct | ||
| Mark A. Kronenfeld | PCRX | Stock Option (Right to Buy) | Award | 11,279 | 11,279 | 11 Jun 2025 | Direct | |||
| Abraham Ceesay | PCRX | Common Stock | Award | 117.8% | 6,163 | 11,393 | 11 Jun 2025 | Direct | ||
| Abraham Ceesay | PCRX | Stock Option (Right to Buy) | Award | 11,279 | 11,279 | 11 Jun 2025 | Direct | |||
| Mark Froimson | PCRX | Common Stock | Award | 42.6% | 6,163 | 20,636 | 11 Jun 2025 | Direct | ||
| Mark Froimson | PCRX | Stock Option (Right to Buy) | Award | 11,279 | 11,279 | 11 Jun 2025 | Direct | |||
| Marcelo Bigal | PCRX | Common Stock | Award | 60.8% | 6,163 | 16,305 | 11 Jun 2025 | Direct | ||
| Marcelo Bigal | PCRX | Stock Option (Right to Buy) | Award | 11,279 | 11,279 | 11 Jun 2025 | Direct | |||
| Michael J. Yang | PCRX | Common Stock | Award | 85.2% | 6,163 | 13,393 | 11 Jun 2025 | Direct | ||
| Michael J. Yang | PCRX | Stock Option (Right to Buy) | Award | 11,279 | 11,279 | 11 Jun 2025 | Direct | |||
| Christopher Christie | PCRX | Common Stock | Award | 58.8% | 6,163 | 16,654 | 11 Jun 2025 | Direct | ||
| Christopher Christie | PCRX | Stock Option (Right to Buy) | Award | 11,279 | 11,279 | 11 Jun 2025 | Direct | |||
| Alethia Young | PCRX | Common Stock | Award | 117.8% | 6,163 | 11,393 | 11 Jun 2025 | Direct | ||
| Alethia Young | PCRX | Stock Option (Right to Buy) | Award | 11,279 | 11,279 | 11 Jun 2025 | Direct | |||
| Laura Brege | PCRX | Common Stock | Award | 35.1% | 6,163 | 23,715 | 11 Jun 2025 | Direct | ||
| Laura Brege | PCRX | Stock Option (Right to Buy) | Award | 11,279 | 11,279 | 11 Jun 2025 | Direct | |||
| Lauren Riker | PCRX | Common Stock | Sale | -8.56% | $146,208 | $26.21 | -5,578 | 59,564 | 04 Jun 2025 | Direct |
| Kristen Williams | PCRX | Common Stock | Sale | -8.17% | $377,226 | $26.24 | -14,376 | 161,574 | 04 Jun 2025 | Direct |
| Lauren Riker | PCRX | Common Stock | Tax liability | -4.92% | -3,374 | 65,142 | 03 Jun 2025 | Direct |